| Home | Search | Study Topics | Glossary |
|
|
|
 |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||||
| Sponsored by: |
Eisai China Inc. |
| Information provided by: | Eisai Medical Research Inc. |
| ClinicalTrials.gov Identifier: | NCT00474409 |
Purpose
To investigate efficacy and safety of Betahistine Mesilate in the treatment of patients with vertigo caused by posterior circulation infarction.
| Condition | Intervention | Phase |
|
Vertigo |
Drug: Merislon |
Phase IV |
| MedlinePlus related topics: | Dizziness and Vertigo |
| ChemIDplus related topics: | Betahistine Betahistine dihydrochloride |
| Study Type: | Interventional |
| Study Design: | Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment, Safety/Efficacy Study |
| Official Title: | A Multicenter, Placebo-Controlled Double-Blind Study To Evaluate The Efficacy And Safety Of Betahistine Mesilate In The Treatment Of Patients With Vertigo Caused By Cerebral Infarction In Posterior Circulation |
Eligibility
| Ages Eligible for Study: | 18 Years to 80 Years |
| Genders Eligible for Study: | Both |
Inclusion Criteria:
Clinical diagnosis of posterior circulation infarction and vertigo occurring within 1 month after the infarction.
Contacts and Locations| Contact: Yin | 86-21-62883118 |
| China | |||||
| Beijing Tiantan Hospital | Recruiting | ||||
| Beijing, China, 100050 | |||||
| Beijing Hospital | Recruiting | ||||
| Beijing, China, 100730 | |||||
| Shanghai Huashan Hospital | Recruiting | ||||
| Shanghai, China, 200040 | |||||
| Shanghai Renji Hospital | Recruiting | ||||
| Shanghai, China, 20001 | |||||
| Eisai China Inc. |
| Principal Investigator: | Wang Yong Jun | Beijing Tiantan Hospital |
More Information
| Study ID Numbers: | MRS-CHN-001 |
| First Received: | May 3, 2007 |
| Last Updated: | September 11, 2007 |
| ClinicalTrials.gov Identifier: | NCT00474409 |
| Health Authority: | China: State Food and Drug Administration |
|
|
|
|
|
|
